Amicogen registers European patent for next-generation 7-ACA synthesis enzyme
Predicted impact: Low
European patent registration is small and vague for near-term financials.
Amicogen아미코젠
092040 · KOSDAQ · ₩092040 · 아미코젠
₩915▲ ₩1 (0.11%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −71.85%
- Market cap
- ₩65B
- Enterprise value
- ₩86B
- P/E
- —
- P/B
- 0.5×
- Dividend yield
- 0.0%
- ROE
- −16.4%
- Net margin
- −41.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−72.5% from the high
₩787Today: ₩901 – ₩925₩3,325
Returns
- 1W−8.0%
- 1M−2.1%
- 3M−17.9%
- 6M−51.6%
- YTD−48.7%
- 1Y−71.8%
- Volume today
- 199,486
- 0.7× the 20-day average
- Traded today
- ₩182M
- Listed shares
- 70,655,387
- EPS (12 months)
- −₩273
- Earnings yield −29.8%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
- Oct 29AGM Extraordinary shareholders' meeting
- Nov 9Earnings Expected · Preliminary results
- Nov 12AGM Extraordinary shareholders' meeting
- Nov 16Earnings Expected · 3Q results
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 38 of 100 (50 is a normal day for this stock).
- MomentumFlat2% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Amicogen stock overview
Amicogen (아미코젠, KRX: 092040) is listed on KOSDAQ, in the Food & Beverage sector. Amicogen is a Korean industrial biotechnology company founded in 2000 that develops and commercializes specialty enzymes for pharmaceuticals, including CX enzyme used in producing the cephalosporin antibiotic raw material 7-ACA. Its shares closed at ₩915 on Oct 27, 2026, up 0.11% on the day, giving it a market value of ₩65B.
Key facts
- Market cap
- ₩65B
- Sector
- Food & Beverage
- Latest price change
- +0.11%
- As of
- Oct 27, 2026
- Main business
- Amicogen is a Korean industrial biotechnology company founded in 2000 that develops and commercializes specialty enzymes for pharmaceuticals, including CX enzyme used in producing the cephalosporin antibiotic raw material 7-ACA.
Quick answers about Amicogen
- What does Amicogen do?
- Amicogen is a Korean industrial biotechnology company founded in 2000 that develops and commercializes specialty enzymes for pharmaceuticals, including CX enzyme used in producing the cephalosporin antibiotic raw material 7-ACA. It also sells health care ingredients such as N-acetylglucosamine, pinitol/D-chiro-inositol, and collagen peptides, along with the K-NUTRA brand and bio-pharmaceutical materials such as Protein A resin and culture media. The company operates in Korea with manufacturing facilities in Jinju and Songdo, and is developing enzymes for other penicillin and cephalosporin antibiotics.
- What is the market cap of Amicogen?
- The market capitalisation of Amicogen was ₩65B at the close on Oct 27, 2026.
- Who are the largest shareholders of Amicogen?
- According to the latest official filings, the largest reported holders are Maga Partners Investment Partnership (4.28%, as of May 4, 2026); Shin Yong-chul (3.69%, as of Mar 28, 2025); National Pension Service (0.37%, as of Dec 31, 2023).
- When is the next earnings report from Amicogen?
- Korean companies rarely announce results dates in advance. Based on when Amicogen filed the same report in past years, its next preliminary results is expected around Nov 7, 2026.
- Does the National Pension Service own Amicogen?
- Yes. The National Pension Service held 0.37% of Amicogen shares as of Dec 31, 2023.
Company profile
Amicogen is a Korean industrial biotechnology company founded in 2000 that develops and commercializes specialty enzymes for pharmaceuticals, including CX enzyme used in producing the cephalosporin antibiotic raw material 7-ACA. It also sells health care ingredients such as N-acetylglucosamine, pinitol/D-chiro-inositol, and collagen peptides, along with the K-NUTRA brand and bio-pharmaceutical materials such as Protein A resin and culture media. The company operates in Korea with manufacturing facilities in Jinju and Songdo, and is developing enzymes for other penicillin and cephalosporin antibiotics.
Written by AI from the company's latest annual report.
- Korean name
- 아미코젠
- Sector
- Food & Beverage
- Themes
- Biotech (new drugs)
- CEO
- 표쩌
- Founded
- May 2000
- Listed
- Sep 2013
- Listed shares
- 70,655,387
- Fiscal year ends
- Month 12
- Website
- www.amicogen.com
Similar companies
- Samyang Foods003230 · ₩8.5T₩1,133,000+1.52%
- Orion271560 · ₩4.4T₩111,500−1.33%
- CJ Cheiljedang097950 · ₩2.5T₩168,700−0.71%
- Nongshim004370 · ₩2.4T₩393,0000.00%
- Otoki007310 · ₩1.2T₩307,500−0.97%
- Hite Jinro000080 · ₩1.1T₩15,660−1.20%
- Lotte Wellfood280360 · ₩1.1T₩118,500−0.08%
- Lotte Chilsung Beverage005300 · ₩881B₩95,000+1.39%
Recent news
Amicogen Breaks Through European Patent, Pushes for Global Antibiotics Production Line Entry in 2027
Predicted impact: Low
European patent win; long-dated production plans, no size given.
Recent filings
See all- Amended: Shareholders' meeting calledOct 12, 2026
- [Amended] Notice of Shareholder Register Closure Period or Record Date SettingOct 12, 2026
- Amended: Half-year report (Jun 2026)Oct 12, 2026
- Designation as Unfaithful Disclosure Company (Two Retractions of Disclosure)Sep 28, 2026
- Notice of Designation as Unfaithful Disclosure Entity (Two Cases of Disclosure Reversal)Sep 3, 2026
Titles in Korean until English translations are added.
Also known as: Amicogen / 아미코젠 / 092040 / KRX:092040
Source: KRX statistical information